- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
Updated results of the Phase III PERSEUS trial evaluating dara-VRd in newly diagnosed myeloma
In this video, Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, The Netherlands, provides an update on the Phase III PERSEUS trial (NCT03710603), which demonstrated the superiority of quadruplet therapy with daratumumab combined with bortezomib, lenalidomide, and dexamethasone (dara-VRd) versus VRd for the treatment of newly diagnosed multiple myeloma (MM). Prof. Sonneveld discusses ongoing follow-up analyses evaluating long-term progression-free survival, circulating tumor cells (CTCs), and outcomes among high-risk patients who achieve measurable residual disease (MRD) negativity. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео Updated results of the Phase III PERSEUS trial evaluating dara-VRd in newly diagnosed myeloma канала VJHemOnc – Video Journal of Hematology & HemOnc
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео Updated results of the Phase III PERSEUS trial evaluating dara-VRd in newly diagnosed myeloma канала VJHemOnc – Video Journal of Hematology & HemOnc
Speaker: Pieter Sonneveld Institution: Erasmus MC Event: COMy 2026 Format: Interview Subject: Multiple Myeloma Field: Trial Updates Field: Treatment Field: MRD Field: Immuno-Oncology Medicines: Antibodies Medicines: Daratumumab Medicines: Bortezomib Medicines: Lenalidomide Medicines: Dexamethasone Trial: PERSEUS dara-VRd MM NCT03710603
Комментарии отсутствуют
Информация о видео
21 мая 2026 г. 14:22:56
00:02:07
Другие видео канала
Insights into the potential for a cure in myeloma: MRD negativity & CAR-T therapies
How may the subcutaneous OBI version of isatuximab impact the QoL of patients with MM?
Frontline and R/R myeloma: an overview of the current treatment landscape
Genomics and immunotherapy: reshaping high-risk multiple myeloma treatment
Where do bispecifics and CAR-T stand in the current treatment landscape of Waldenström’s?
Genomic sequencing guides personalized treatment in multiple myeloma
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
ClonoSEQ in myeloma: how does it fit into a patient-centric diagnostic pathway?
Bispecific antibodies in myeloma: community care considerations & unmet needs
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
Key unmet needs in functional high-risk myeloma: a clinical perspective
How is the role of sFLC evolving for assessing disease response in myeloma?
REALiTEC cohort 2: teclistamab shows favorable real-world outcomes in R/R myeloma
Insights into the updated genomic consensus definition for high-risk newly diagnosed myeloma
Recent advances and unmet needs in smoldering multiple myeloma
How may whole body MRI enhance patient management strategies in myeloma?
Expanding access to bispecific antibodies and CAR T-cell therapy in myeloma
Insights into the disease biology & role of T-cell redirecting therapies in EMD
How do tumor subclones and T-cell dynamics influence ibrutinib responses in Waldenström’s?
Insights into functional high-risk myeloma and how to adapt treatment for these patients
